Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia

Hyo Jeong Lee; Jungeun Lee; Pyeonghwa Jeong; Jungil Choi; Juhwa Baek; Su Jin Ahn; Yeongyu Moon; Jeong Doo Heo; Young Hee Choi; Young-Won Chin; Yong-Chul Kim; Sun-Young Han

doi:10.18632/oncotarget.25141

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia

PDF | How to cite

Oncotarget. 2018; 9:20219-20219. https://doi.org/10.18632/oncotarget.25141

Metrics: PDF 2003 views | ?

Hyo Jeong Lee^1,*, Jungeun Lee^2,*, Pyeonghwa Jeong^3,*, Jungil Choi⁴, Juhwa Baek¹, Su Jin Ahn¹, Yeongyu Moon⁴, Jeong Doo Heo⁴, Young Hee Choi⁵, Young-Won Chin⁵, Yong-Chul Kim^2,3 and Sun-Young Han¹

¹ College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju, Republic of Korea
² School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea
³ Biomedical Science and Engineering, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea
⁴ Gyeongnam Department of Environment Toxicology and Chemistry, Korea Institutes of Toxicology, Jinju, Republic of Korea
⁵ College of Pharmacy and BK21PLUS R-FIND Team, Dongguk University-Seoul, Goyang, Republic of Korea ^* These authors contributed equally to the work

Published: April 13, 2018

This article has been corrected: The correct author affiliations citations are given below:

Original article: Oncotarget. 2018; 9:924-936. DOI: https://doi.org/10.18632/oncotarget.23221.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25141

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia